NASDAQ OMX

Immunicum AB: Immunicums VD presenterar bolaget vid konferenser i juni

Dela

Pressmeddelande

30 May 2017

Immunicums VD presenterar bolaget vid konferenser i juni


Immunicum AB  (publ; First North Premier: IMMU.ST) ett bioteknikbolag som utvecklar nya immunaktiverande cancerbehandlingar för ett antal solida tumörer tillkännager idag att Carlos de Sousa, VD för Immunicum, har blivit inbjuden att presentera bolaget vid ett antal konferenser i juni och har även blivit tillfrågad att delta i en panel med titeln "New Frontiers in Oncology." Dessutom kommer företaget att delta på 2017 BIO International Convention.

Sachs Associates 3rd Annual Immuno-Oncology BD&L and Investment Forum
Datum: 2 juni, 2017
Tidpunkt för Immunicums presentation: 11:10 CST
Plats: Hyatt Centric Chicago Magnificent Mile Hotel, Chicago, Illinois

Labiotech Refresh
Datum: 8 juni, 2017
Paneldebatt: "New Frontiers in Oncology" 10:30 CET
Plats: Spreewerkstätten, Berlin, Tyskland

Småbolagsdagen
Datum: 12 juni, 2017
Tidpunkt för Immunicums presentation: 9:20 - 9:50 CET
Plats: Sheraton Hotel Stockholm, Stockholm, Sverige

För de som inte kan delta så kommer presentationen från Småbolagsdagen att finnas tillgänglig i efterhand på Immunicums hemsida och kan även följas live på www.smabolagsdagen.net.

2017 BIO International Convention (endast deltagare)
Datum: 19-22 juni, 2017
Plats: San Diego Convention Center, San Diego, Californien

För ytterligare information kontakta:

Carlos de Sousa, VD, Immunicum
Telefon: +46 (0) 31 41 50 52
E-post: info@immunicum.com

Investerarrelationer, Sverige

Helena Stångberg
Hallvarsson & Halvarsson
Telefon: + 46 709 71 12 53
E-post: helena.stangberg@halvarsson.se

Investerarrelationer och Mediakontakt, EU/USA

MacDougall Biomedical Communications
Gretchen Schweitzer eller Stephanie May
Telefon: +49 89 2424 3494 eller + 49 175 571 1562
E-post: gschweitzer@macbiocom.com eller smay@macbiocom.com

 

Bolagets Certified Adviser är Redeye AB
Telefon: +46 (0) 8 545 013 31
www.redeye.se

 

 

OM IMMUNICUM AB (PUBL)

Immunicum AB (First North Premier: IMMU.ST) är ett bolag som i klinisk fas utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörformer. Bolagets längst framskridna produkt, INTUVAX®, utvärderas för närvarande i kliniska studier för behandling av njurcancer, levercancer och gastrointestinal stromacellstumör. INTUVAX ® har designats för att kombinera det bästa av två världar: en kostnadseffektiv, cellbaserad (allogen) och lätttillgänglig behandling som har förmågan att utlösa individbaserade och potentiellt ihållande immunsvar mot tumörceller i hela kroppen. www.immunicum.com

 

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

CP Kelco Appoints Didier Viala as New President16.10.2017 15:00Pressmeddelande

ATLANTA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- CP Kelco, a leading global producer of specialty hydrocolloid solutions, announced today that Didier Viala has been appointed President, effective October 1, 2017. Viala replaces Donald Rubright, who served as CP Kelco President since 2006 and will retire at the end of 2017. Viala has also joined the CP Kelco Board of Directors. "As a market leader supplying high-quality hydrocolloid products for a range of foods and beverages, consumer products and industrial applications, CP Kelco will continue to invest in capacity additions, new product and applications development, strategic raw material sourcing, quality and safety management, and sustainability initiatives to support our customers' innovation efforts and growth strategies," Viala said. Over the course of more than 25 years with CP Kelco and its predecessor companies, Viala held leadership roles across a broad spectrum of critical areas, including innovat

LogicBio Therapeutics to Present Preclinical Data at European Society of Gene & Cell Therapy 25th Anniversary Congress in Berlin16.10.2017 15:00Pressmeddelande

· Company co-founder Professor Adi Barzel, Ph.D., to present new proof-of-concept efficacy data CAMBRIDGE, Massachusetts, Oct. 16, 2017 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc., a gene-therapy company with a mission to develop cures for early-onset life-threatening diseases, announced today that its company co-founder, Dr. Adi Barzel, will present new data from its genome-editing platform during the 25th Annual European Society of Gene & Cell Therapy (ESGCT) Congress in two presentations this Wednesday in Berlin, Germany. The ESGCT will be held from October 17-20, 2017, at the bcc Berlin. Dr. Barzel will present data in multiple animal models of disease demonstrating the extended therapeutic potential of LogicBio's proprietary GeneRide(TM) platform technology. The GeneRide technology harnesses the natural power of homologous recombination to enable precise, site-specific in vivo genome editing to deliver therapeutic genetic material without th

Invitation to presentation of LeoVegas third quarter 201716.10.2017 14:35Pressmeddelande

LeoVegas interim report for the third quarter 2017 will be published at 08:00 CET on October 25, 2017. A webcast telephone conference will be held at 09:00 CET the same day, where Gustaf Hagman, CEO and President, and Viktor Fritzén, CFO, will present the results for the third quarter 2017. A possibility will be given to ask questions via the webcast and follow the presentation live. The webcast will be accessible at: https://edge.media-server.com/m6/p/4pk3b55e                   To participate in the conference call by phone, please call one of the following numbers: SE: +46 (0) 8 5352 6408 UK: +44 (0) 20 3427 1914 US: + 1646 254 3364 Confirmation code: 35 35 667          The webcast, which afterwards also will be

Inbjudan till presentation av LeoVegas kvartalsrapport för tredje kvartalet 201716.10.2017 14:35Pressmeddelande

LeoVegas kvartalsrapport för det tredje kvartalet 2017 kommer att publiceras klockan 08:00 den 25 oktober 2017. En webbsänd telefonkonferens kommer att hållas klockan 09:00 samma dag där Gustaf Hagman, VD och koncernchef samt Viktor Fritzén, CFO, presenterar resultatet för det tredje kvartalet 2017. Det kommer att finnas möjlighet att ställa frågor via webbsändningen där även presentationsmaterialet går att följa. Webbsändningen nås på adressen: https://edge.media-server.com/m6/p/4pk3b55e För att delta i telefonkonferensen via telefon, vänligen ring in på något av följande nummer: SE: +46 (0) 8 5352 6408 UK: +44 (0) 20 3427 1914 US: + 1646 254 3364 Bekräftelsekod: 35 35 667 Webbsändningen, som även kan ses i efterhand, och pres

Concurrent Enters Definitive Agreement to Sell Content Delivery & Storage Business to Vecima Networks for $29 Million16.10.2017 14:00Pressmeddelande

Proposed Transaction Expected to Result in Debt Free Balance Sheet with $67 Million in Pro Forma Working Capital ATLANTA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Concurrent Computer Corporation (NASDAQ:CCUR) has entered into a definitive agreement to sell all of the assets of its Content Delivery & Storage Business to Vecima Networks Inc. (TSX:VCM) for a base purchase price of $29 million, subject to adjustment for normalized net working capital.  Headquartered in Victoria, British Columbia, Vecima is a leading designer and manufacturer of innovative network technology solutions. The proposed transaction, which has been approved by the Board of Directors of both companies, is subject to various terms and conditions including stockholder approval from Concurrent. "Vecima believes that the rapid growth in IPTV delivery across both MVPD private CDNs and OTT providers will continue to accelerate.  Concurrent is a recognized leader in storing, protec

Telefonica Deploys ASSIA's GPON Expresse® Solution to optimize Fiber Broadband Performance16.10.2017 14:00Pressmeddelande

REDWOOD CITY, Calif., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Adaptive Spectrum and Signal Alignment, Inc. (ASSIA®). ASSIA and Telefonica announce widespread deployment of ASSIA's GPON Expresse® software across countries in South America: Argentina, Brazil, Chile, Colombia and Peru. GPON Expresse manages gigabit optical broadband networks with diagnostics for improved network performance and service delivery to Telefonica's fiber-based subscribers. GPON Expresse adds to the suite of ASSIA software products currently deployed at Telefonica in Latin America: DSL Expresse® for diagnostics and optimization of high speed DSL networks, and ClearView® for precise network analysis and recommendations for customer care agents and field technicians.  With the GPON Expresse deployment, Telefonica can now benefit from ClearView support across both copper and fiber networks.  By also incorporating ClearView support for Wi-Fi, operators can have complete end-to-end management across their ac

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum